January 14, 2014 10:53 AM | 1 min read
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
In a report published Tuesday, Morgan Stanley analyst David Friedman downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) to Overweight from Equal-weight, raising its price target to $72.00 from $54.00. According to the report, the move was based on a more balanced risk/reward post recent stock strength.“We view Alnylam's technology as potentially transformative and see the prospects for the drugs that have been tested in humans as robust,” the report noted. “In addition, we view the recent Sanofi/Sirna transactions as steps that likely will help maximize the platform from many perspectives. However, in light of the recent stock strength over the past 12 mos, we see a more balanced risk/reward for shares heading into the major TTR program data catalysts in 2H14. Above- expectations TTR data in 2H14 or human proof of concept from an earlier-stage program (e.g. hemophilia) are events that would trigger a valuation re-evaluation.”ALNY closed Tuesday at $93.28 with shares trading up at 40.89 percent.
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.